Showing results (91-100 of 185) with videos related to
Sort By:
Pageof 19
Clinical Therapeutics|May 1, 2018
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and PharmacotherapyZohaib Iqbal, Shazli Azmi, Rahul Yadav, et al.The Journal of Clinical Endocrinology and Metabolism|June 12, 2024
Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver DiseaseTommaso Bucci, Katarzyna Nabrdalik, Francesco Baratta, et al.Clinical Therapeutics|October 22, 2022
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and ManagementScott Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, et al.Journal of Clinical Medicine|February 25, 2023
Artificial Intelligence Based Analysis of Corneal Confocal Microscopy Images for Diagnosing Peripheral Neuropathy: A Binary Classification ModelYanda Meng, Frank George Preston, Maryam Ferdousi, et al.Cardiovascular Diabetology|November 19, 2025
Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research networkEnrico Tartaglia, Tommaso Bucci, Michele Rossi, et al.Journal of Diabetes Research|June 7, 2024
Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative DatabaseMatthew Anson, Ayesha Malik, Sizheng S Zhao, et al.Expert Review of Neurotherapeutics|August 21, 2023
Where Art Thou O treatment for diabetic neuropathy: the sequelYigit Can Guldiken, Ayesha Malik, Ioannis N Petropoulos, et al.Thorax|December 7, 2024
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort dataAlex E Henney, David R Riley, Theresa J Hydes, et al.Journal of the American Heart Association|April 13, 2017
Abnormal Remodeling of Subcutaneous Small Arteries Is Associated With Early Diastolic Impairment in Metabolic SyndromeKaivan Khavandi, Reza Aghamohammadzadeh, Matthew Luckie, et al.Diabetes, Obesity & Metabolism|June 20, 2024
Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysisAlex E Henney, David R Riley, Ben O'Connor, et al.Pageof 19